Locally advanced nonsmall cell lung cancer, due to its varying prognosis, is grouped according to TNM stage IIIA, IIIB and IIIC. Developments over the last 3 years have been focused on the integration of immunotherapy into the combination treatment of a locally definitive therapy (surgery or radiotherapy) and chemotherapy. For concurrent chemoradiotherapy, consolidation therapy with durvalumab was established. Adjuvant targeted therapy has again gained increasing interest. In order to adapt treatment to the specific stage subgroup and its prognosis, fluorodeoxyglucose positron emission tomography/computed tomography and pathological evaluation of the mediastinum are important. Tumours should be investigated for immunological features and driver mutations. Regarding toxicity, evaluation of pulmonary and cardiac function, as well as symptoms and quality of life, is of increasing importance. To improve the management and prognosis of this heterogeneous entity, clinical trials and registries should take these factors into account.

局部晚期非小细胞肺癌由于其预后不同，根据 TNM 分期 IIIA、IIIB 和 IIIC 进行分组。过去 3 年的发展重点是将免疫疗法整合到局部根治性疗法（手术或放射疗法）和化学疗法的联合治疗中。对于同步放化疗，确立了使用度伐鲁单抗的巩固治疗。辅助靶向治疗再次受到越来越多的关注。为了使治疗适应特定分期亚组及其预后，氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描和纵隔病理评估很重要。应研究肿瘤的免疫学特征和驱动突变。关于毒性，肺和心脏功能的评估，以及症状和生活质量，变得越来越重要。为了改善这种异质性实体的管理和预后，临床试验和注册应考虑这些因素。